Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...

The network is called Lunar Surface Communication System (LSCS), and it is basically a replica of the 4G/LTE cellular technology currently used on a very large scale by the humans of Earth.

Two new “pioneering” open-access scale-up facilities focused on advancing cellular agriculture are at the centre of a €12.5m investment grant from the Dutch National Growth Fund for Cellular ...

It looks like T-Mobile is now accepting customers into the free beta program for SpaceX’s cellular Starlink service—but only if you have the latest Samsung handsets. On Tuesday, a number of T ...

8, 2024. (AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

Johnson & Johnson is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, people familiar with the matter said. A ...

(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

Johnson & Johnson on Monday said it has agreed to acquire Intra-Cellular Therapies, a developer of drugs for diseases of the brain, for $132 per share, or about $14.6 billion. The announcement of the ...

The potential acquisition comes as J&J seeks to bolster its portfolio. Credit: Skorzewiak/Shutterstock. Johnson & Johnson (J&J) has announced it will acquire Intra-Cellular Therapies, a company ...

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will ...